When was icatibant first approved by the FDA?

The FDA approved icatibant (Firazyr) on September 16, 2011, for acute angioedema attacks in hereditary angioedema patients. It was the first FDA-approved therapy designed specifically for acute HAE attacks, based on evidence from the FAST-3 and FAST-1 Phase III trials.

How many clinical trials were conducted for icatibant?

Thirty-two registered clinical trials supported icatibant's development, covering pharmacokinetics, efficacy, safety, and post-approval outcomes. These trials enrolled hundreds of HAE patients and provided a robust evidence base for regulatory approval across the US, EU, and Canada.

What was the key efficacy finding in icatibant's pivotal trials?

FAST-3 showed icatibant reduced median time to symptom relief to approximately 2 hours versus 30 hours for placebo. This decisive effect on attack duration was the primary basis for FDA and EMA approval and represented a significant clinical advance for HAE management.

Is icatibant approved in countries outside the US and EU?

Yes. Health Canada approved icatibant in 2012, and it has been approved or licensed in multiple other regions. Approval status varies by country; icatibant is typically available by prescription in developed healthcare systems, often through specialized hemophilia centers.

What is the mechanism of action that icatibant uses?

Icatibant is a selective antagonist of the bradykinin B2 receptor. Hereditary angioedema involves excessive bradykinin production; blocking B2 receptor signaling interrupts the inflammatory cascade that causes acute angioedema attacks, providing rapid symptom relief.

Icatibant Regulatory Timeline: FDA Approval to Market

Icatibant is a selective bradykinin B2 receptor antagonist that completed a landmark regulatory journey to become the first effective acute treatment for hereditary angioedema (HAE) attacks. Developed by Jerini AG and acquired by Shire (now Takeda), icatibant earned FDA approval in 2011, followed by EMA authorisation and Health Canada approval, marking a major shift in HAE management. The compound's path from preclinical discovery through Phase III trials involved 32 registered clinical studies and represents one of the most significant advances in treating this life-threatening rare disease.

Discovery and Early Development (2000–2005)

Icatibant's story begins with a molecular insight: hereditary angioedema, a rare genetic disorder affecting approximately 1 in 50,000 people, stems from deficient or dysfunctional C1 esterase inhibitor, leading to unchecked bradykinin production. Jerini AG, a Berlin-based biotech company, identified the bradykinin B2 receptor as a therapeutic target and synthesized icatibant as a selective antagonist to block bradykinin-mediated inflammation.

The preclinical rationale was compelling: blocking bradykinin signalling could interrupt the pathophysiological cascade that causes acute angioedema attacks—unpredictable swelling of the skin, abdomen, and potentially the airway. Early studies in animal models and in vitro systems demonstrated that icatibant could suppress bradykinin-induced vascular permeability, laying the groundwork for human trials.

Phase I and II Studies (2005–2008)

Icatibant entered human testing with Phase I safety and tolerability studies, establishing a baseline understanding of pharmacokinetics and dose escalation. The early trials revealed that icatibant was absorbed rapidly after subcutaneous injection, with peak plasma concentrations within 30 minutes—a critical property for treating acute attacks that can develop within hours.

Phase II studies followed, focusing on efficacy and optimal dosing in HAE patients experiencing acute attacks. Research showed that icatibant significantly reduced attack duration compared to placebo, with patients reporting symptom improvement within 2 hours of administration. These trials enrolled small patient cohorts—reflecting the rarity of HAE—but the effect sizes were large enough to warrant Phase III expansion.

Phase III Pivotal Trials (2008–2010)

The regulatory path accelerated with two pivotal Phase III studies: FAST-3 (completed 2009) and FAST-1 (completed 2010). These trials were specifically designed to support regulatory submissions across multiple regions.

FAST-3 enrolled HAE patients experiencing acute angioedema attacks and randomized them to receive either icatibant 30 mg subcutaneously or placebo. The trial demonstrated that icatibant reduced the median time to symptom relief to 2 hours compared to 30 hours for placebo—a clinically decisive difference. The trial was halted early for efficacy, a decision that strengthened the regulatory case.

FAST-1 examined icatibant in a broader HAE population and confirmed the efficacy signal, with consistent reduction in attack duration and severity across patient subgroups. These studies enrolled patients with documented HAE due to C1-INH deficiency (Type I or II) and evaluated multiple attacks per patient over a treatment period, providing robust safety and efficacy data.

Across the icatibant development program, 32 clinical trials were registered, providing a comprehensive evidence base covering efficacy, safety, pharmacokinetics, and post-marketing surveillance.

FDA Approval (September 2011)

On September 16, 2011, the U.S. Food and Drug Administration (FDA) approved icatibant injection under the brand name Firazyr for the treatment of acute angioedema attacks in adults with hereditary angioedema. This marked the first FDA-approved therapy specifically designed for acute HAE attacks—previously, patients relied on off-label use of C1-INH concentrates, FFP (fresh frozen plasma), or treatment with no proven efficacy.

The FDA approval was based on the FAST-3 and FAST-1 data, which demonstrated rapid symptom relief and a favorable safety profile in patients with moderate-to-severe attacks. The approval letter cited icatibant's novel mechanism (selective B2 receptor antagonism) and the unmet medical need in HAE as key factors supporting accelerated review.

European Medicines Agency Authorisation (2011)

Following FDA approval, the European Medicines Agency (EMA) granted conditional marketing authorisation for Firazyr on November 24, 2011. The EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed the same pivotal trial data and recommended approval for acute angioedema attacks in adult HAE patients. The conditional status reflected the rarity of HAE and the difficulty in conducting large post-approval studies, but the CHMP noted the high clinical benefit relative to the limited evidence requirements for orphan drugs.

Health Canada Approval (2012)

Health Canada approved icatibant in 2012 under the same indication, extending access to Canadian HAE patients and completing approval in the three major regulatory jurisdictions (US, EU, Canada).

Post-Approval Development and Market Integration (2012–Present)

Following approval, icatibant entered post-marketing surveillance and real-world studies. Long-term follow-up data confirmed the sustained efficacy and safety profile observed in trials, with consistent attack duration reduction and a low rate of serious adverse events.

In 2019, Takeda Pharmaceutical (which acquired Shire in 2018, and Jerini in 2006) continued to expand the clinical evidence base. Additional studies examined icatibant use in specific subpopulations—including pediatric patients and those with estrogen-dependent HAE—though pediatric approval came later following dedicated pediatric trials.

Icatibant's regulatory status also benefited from its orphan drug designation in both the US and EU, a classification that recognizes the severe and life-threatening nature of HAE and provides regulatory incentives including extended patent exclusivity and fee reductions for regulatory submissions.

Clinical Trial Landscape

The 32 registered clinical trials supporting icatibant span multiple phases and endpoints:

Pharmacokinetic studies characterizing absorption, distribution, metabolism, and excretion
Efficacy trials measuring attack duration, symptom resolution, and quality of life
Safety and tolerability studies in diverse HAE populations
Comparative studies examining icatibant against historical controls and other HAE treatments
Observational studies tracking real-world outcomes post-approval

These trials collectively enrolled hundreds of HAE patients, a significant achievement given the disease's rarity (estimated 1 in 50,000 people globally, with only ~10,000–15,000 diagnosed patients in the US).

Current Regulatory Status

Icatibant (Firazyr) remains an FDA-approved, EMA-authorised, and Health Canada-approved therapy for acute angioedema attacks in HAE patients. It is administered as a 30 mg subcutaneous injection and is typically available only by prescription, often within specialized hemophilia/immunodeficiency centers due to the rarity of HAE.

The regulatory journey for icatibant exemplifies how orphan drug pathways, combined with robust clinical trial data, can accelerate approval for life-threatening rare diseases. The drug's entry into the market transformed HAE management and established the bradykinin B2 receptor as a validated therapeutic target for angioedema.

Related Compounds and Mechanisms

Icatibant's success inspired development of other bradykinin pathway modulators. Ecallantide, a kallikrein inhibitor, was approved around the same time for acute HAE attacks. Lanadelumab, a monoclonal antibody against plasma kallikrein, later earned approval for HAE prophylaxis. These compounds demonstrate the expanding arsenal of HAE treatments targeting overlapping biochemical pathways.

For deeper understanding of icatibant's mechanism, see bradykinin and hereditary angioedema.

Icatibant Regulatory History: A Decade of Approval Milestones